215 related articles for article (PubMed ID: 17625806)
21. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.
Theurillat JP; Ingold F; Frei C; Zippelius A; Varga Z; Seifert B; Chen YT; Jäger D; Knuth A; Moch H
Int J Cancer; 2007 Jun; 120(11):2411-7. PubMed ID: 17294444
[TBL] [Abstract][Full Text] [Related]
22. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.
Errington JA; Conway RM; Walsh-Conway N; Browning J; Freyer C; Cebon J; Madigan MC
Br J Ophthalmol; 2012 Mar; 96(3):451-8. PubMed ID: 22190731
[TBL] [Abstract][Full Text] [Related]
23. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
Napoletano C; Bellati F; Tarquini E; Tomao F; Taurino F; Spagnoli G; Rughetti A; Muzii L; Nuti M; Benedetti Panici P
Am J Obstet Gynecol; 2008 Jan; 198(1):99.e1-7. PubMed ID: 18166319
[TBL] [Abstract][Full Text] [Related]
24. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L
Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033
[TBL] [Abstract][Full Text] [Related]
25. MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma.
Bujas T; Marusic Z; Peric Balja M; Mijic A; Kruslin B; Tomas D
Eur J Histochem; 2011 Mar; 55(1):e7. PubMed ID: 21556122
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
27. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
Zelba H; Weide B; Martens A; Derhovanessian E; Bailur JK; Kyzirakos C; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries J; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Aug; 20(16):4390-9. PubMed ID: 24938524
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC
J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080
[TBL] [Abstract][Full Text] [Related]
31. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.
Jungbluth AA; Chen YT; Stockert E; Busam KJ; Kolb D; Iversen K; Coplan K; Williamson B; Altorki N; Old LJ
Int J Cancer; 2001 Jun; 92(6):856-60. PubMed ID: 11351307
[TBL] [Abstract][Full Text] [Related]
33. Tumor antigen expression in melanoma varies according to antigen and stage.
Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
[TBL] [Abstract][Full Text] [Related]
36. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
[TBL] [Abstract][Full Text] [Related]
37. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
38. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.
Kerkar SP; Wang ZF; Lasota J; Park T; Patel K; Groh E; Rosenberg SA; Miettinen MM
J Immunother; 2016 May; 39(4):181-7. PubMed ID: 27070449
[TBL] [Abstract][Full Text] [Related]
39. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
[TBL] [Abstract][Full Text] [Related]
40. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
von Boehmer L; Mattle M; Bode P; Landshammer A; Schäfer C; Nuber N; Ritter G; Old L; Moch H; Schäfer N; Jäger E; Knuth A; van den Broek M
Cancer Immun; 2013; 13():12. PubMed ID: 23882157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]